AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Inc. announces the publication of the CEO Corner segment featuring Thomas Equels, discussing corporate overview, business outlook, and the AIM opportunity.
03/22/2024 - 08:55 AM
OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, provided a corporate overview, a business outlook and discussed the AIM opportunity as part of the Virtual Investor Lunch Break series.
The CEO Corner segment is now available here .
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
What is the latest announcement from AIM ImmunoTech Inc.?
AIM ImmunoTech Inc. announced the publication of the CEO Corner segment on their website.
Who is featured in the CEO Corner segment?
Thomas Equels, the Chief Executive Officer of AIM ImmunoTech, is featured in the CEO Corner segment.
What topics are discussed in the CEO Corner segment?
The CEO Corner segment covers a corporate overview, business outlook, and the AIM opportunity.
Where can the CEO Corner segment be accessed?
The CEO Corner segment is available on the Company's website.
AIM Rankings
#3581 Ranked by Stock Gains
AIM Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Ocala
About AIM
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
